Zika Virus
Conditions
Keywords
mRNA-1325, Zika vaccine
Brief summary
The clinical study will assess the safety, tolerability, and immunogenicity of mRNA-1325 in healthy adult subjects.
Interventions
BIOLOGICALmRNA-1325
Escalating dose levels
OTHERPlacebo
Sponsors
Biomedical Advanced Research and Development Authority
ModernaTX, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
Inclusion * 18 to 49 years of age * Body mass index between 18 and 35 kg/m2 * In good health as determined by medical history * Female subjects must be non pregnant and non lactating and meet one of the following criteria: a) post menopausal b) surgically sterile * Women of childbearing potential must agree to be heterosexually inactive or agree to consistently use any of the following methods of contraception from at least 21 days prior to enrollment and through 3 months after the final vaccination * Male subjects must use an acceptable method of birth control throughout the entire study and agree to refrain from donation of sperm from the time of first vaccination until 3 months following the last vaccination * Agrees to comply with the study procedures and provides written informed consent * Has access to a consistent and reliable means of telephone contact and agrees to stay in contact with the study site for the duration of the study, to provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study Exclusion * Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care * A history of active cancer (malignancy) in the last 10 years * Female of childbearing potential and has a positive pregnancy test at screening or on the day of vaccination * Administration of an investigational product within 60 days, or 5 half-lives, whichever is longer * Administration of any live attenuated vaccines within 4 weeks before enrollment or inactive vaccines within 2 weeks before enrollment, or plans to receive any vaccine during the active vaccination period * Prior administration of a vaccine for Zika or dengue vaccine, a history of confirmed Zika or dengue infection, or has lived in or visited any Zika-endemic area greater than 4 weeks in duration * Prior administration of investigational agent using formulations similar to mRNA-1325 * A history of hypersensitivity or serious reactions to previous vaccinations * Any known or suspected autoimmune disease or immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination * A history of inflammatory arthritis * Any neurologic disorder * A history of febrile disease with arthritis or arthralgia within 2 weeks of dose administration. * Prior administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study drug or plans to receive such products at any time during the study * Any chronic administration of an immunosuppressant or other immune modifying drug * Any acute illness at the time of enrollment * Any significant disorder of coagulation requiring ongoing or intermittent treatment * A history of idiopathic urticaria * A history of alcohol abuse or drug addiction * A positive test result for drugs of abuse * The subject has any abnormality or permanent body art (eg, tattoo) that, in the opinion of the investigator, would obstruct the ability to observe local reactions at the injection site * Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study drug or interpretation of study results * A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies * Donation of blood or blood products \> 450 mL within 30 days of dosing. * Abnormal vital signs or screening safety laboratory test results including liver enzyme tests * Is an employee or first degree relative of the Sponsor, CRO, or study site personnel
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Up to 7 days post-vaccination 1 (up to 8 days) | Solicited adverse reactions (ARs) (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema, and injection site induration/swelling. Systemic ARs included: body temperature (oral), generalized myalgia (muscle ache or pain), generalized arthralgia (joint ache or pain), headache, fatigue/malaise (unusual tiredness), nausea/vomiting, chills, and rash. Data for this outcome measure is reported up to 7 days after the first study vaccination only. A summary of all serious AEs (SAEs) and nonserious AEs (Other), regardless of causality, is in Reported Adverse Events section. |
| Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Up to 7 days post-vaccination 2 (Day 29 to Day 36) | Solicited adverse reactions (ARs) (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema, and injection site induration/swelling. Systemic ARs included: body temperature (oral), generalized myalgia (muscle ache or pain), generalized arthralgia (joint ache or pain), headache, fatigue/malaise (unusual tiredness), nausea/vomiting, chills, and rash. Data for this outcome measure is reported up to 7 days after the second study vaccination only. A summary of all serious AEs (SAEs) and all nonserious AEs (Other), regardless of causality, is in Reported Adverse Events section. |
| Part A: Number of Participants With Unsolicited Adverse Events | Up to Day 392 (all AEs considered an SAE were collected till end of study [Day 392]; the Other AEs [non-SAE] were collected up to Day 57) | An unsolicited AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The treatment-emergent AEs are defined as any event not present before exposure to study drug or any event already present that worsened in intensity or frequency after exposure. A summary of all SAEs and all nonserious AEs (Other) reported up to the end of the study, regardless of causality, is located in the Reported Adverse Events section. |
| Part A: Number of Participants With Medically-Attended Adverse Events (MAAEs) | Up to 1 year post-vaccination (Day 392) | An MAAE is an AE that leads to an unscheduled visit to an healthcare practitioner. A summary of all SAEs and all nonserious AEs (Other), regardless of causality, is located in the Reported Adverse Events section. |
| Part B: Number of Participants With Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) | Up to 1 year post-vaccination (Day 392) | An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions was a congenital anomaly/birth defect, or was an important medical event. AESIs included potentially immune-mediated medical conditions (autoimmune or autoinflammatory diseases) that may have the theoretical potential for association with novel vaccines. A summary of all SAEs and all nonserious AEs (Other), regardless of causality, is located in the Reported Adverse Events section. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Baseline, 28 days post each vaccination (Days 29 and 57) | GMT 95% CI is calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. |
Countries
United States
Participant flow
Pre-assignment details
This was a 2-part study. Part A was conducted for 28 days following the second vaccination. Once the participants completed the final visit in Part A, they were entered into Part B. Part B was conducted for 12 months following the second vaccination in Part A.
Participants by arm
| Arm | Count |
|---|---|
| mRNA-1325 10 mcg Participants received mRNA-1325 10 mcg IM injection on Days 1 and 29. | 25 |
| mRNA-1325 25 mcg Participants received mRNA-1325 25 mcg as an IM injection on Days 1 and 29. | 24 |
| mRNA-1325 100 mcg Participants received mRNA-1325 100 mcg as an IM injection on Days 1 and 29. | 25 |
| Placebo Participants received placebo matched to mRNA-1325 as an IM injection on Days 1 and 29. | 16 |
| Total | 90 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 | 1 | 0 |
| Overall Study | Lost to Follow-up | 1 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 1 | 1 | 1 |
Baseline characteristics
| Characteristic | mRNA-1325 10 mcg | mRNA-1325 25 mcg | mRNA-1325 100 mcg | Placebo | Total |
|---|---|---|---|---|---|
| Age, Continuous | 33.9 years STANDARD_DEVIATION 8.57 | 34.4 years STANDARD_DEVIATION 9.42 | 35.3 years STANDARD_DEVIATION 8.59 | 38.9 years STANDARD_DEVIATION 8.69 | 35.3 years STANDARD_DEVIATION 8.86 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 7 Participants | 5 Participants | 1 Participants | 2 Participants | 15 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 17 Participants | 19 Participants | 24 Participants | 14 Participants | 74 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 23 Participants | 22 Participants | 24 Participants | 15 Participants | 84 Participants |
| Sex: Female, Male Female | 16 Participants | 14 Participants | 13 Participants | 10 Participants | 53 Participants |
| Sex: Female, Male Male | 9 Participants | 10 Participants | 12 Participants | 6 Participants | 37 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 25 | 0 / 24 | 0 / 25 | 0 / 16 |
| other Total, other adverse events | 24 / 25 | 23 / 24 | 25 / 25 | 12 / 16 |
| serious Total, serious adverse events | 1 / 25 | 0 / 24 | 0 / 25 | 0 / 16 |
Outcome results
Primary
Part A: Number of Participants With Medically-Attended Adverse Events (MAAEs)
An MAAE is an AE that leads to an unscheduled visit to an healthcare practitioner. A summary of all SAEs and all nonserious AEs (Other), regardless of causality, is located in the Reported Adverse Events section.
Time frame: Up to 1 year post-vaccination (Day 392)
Population: The Safety set included all participants in Randomized Set who received at least 1 dose of study drug (mRNA-1325 or placebo).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| mRNA-1325 10 mcg | Part A: Number of Participants With Medically-Attended Adverse Events (MAAEs) | 5 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Medically-Attended Adverse Events (MAAEs) | 3 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Medically-Attended Adverse Events (MAAEs) | 3 Participants |
| Placebo | Part A: Number of Participants With Medically-Attended Adverse Events (MAAEs) | 1 Participants |
Primary
Part A: Number of Participants With Solicited Adverse Events- Vaccination 1
Solicited adverse reactions (ARs) (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema, and injection site induration/swelling. Systemic ARs included: body temperature (oral), generalized myalgia (muscle ache or pain), generalized arthralgia (joint ache or pain), headache, fatigue/malaise (unusual tiredness), nausea/vomiting, chills, and rash. Data for this outcome measure is reported up to 7 days after the first study vaccination only. A summary of all serious AEs (SAEs) and nonserious AEs (Other), regardless of causality, is in Reported Adverse Events section.
Time frame: Up to 7 days post-vaccination 1 (up to 8 days)
Population: The Safety set included all participants in Randomized Set who received at least 1 dose of study drug (mRNA-1325 or placebo) and provided vaccination 1 safety data.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Diarrhea | 2 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Redness | 0 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Tenderness | 21 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Vomiting | 3 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Fever | 0 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Generalized Arthralgia | 3 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Generalized Myalgia | 8 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Fatigue | 7 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Swelling | 0 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Pain | 17 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Headache | 11 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Generalized Myalgia | 9 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Pain | 20 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Tenderness | 20 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Swelling | 1 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Redness | 0 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Fever | 0 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Vomiting | 0 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Generalized Arthralgia | 3 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Diarrhea | 0 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Headache | 4 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Fatigue | 4 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Diarrhea | 0 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Vomiting | 2 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Fatigue | 4 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Swelling | 1 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Tenderness | 23 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Generalized Arthralgia | 5 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Headache | 10 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Fever | 2 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Pain | 24 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Redness | 1 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Generalized Myalgia | 11 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Tenderness | 3 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Vomiting | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Swelling | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Diarrhea | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Headache | 3 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Generalized Myalgia | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Generalized Arthralgia | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Fatigue | 2 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Redness | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Local Event- Pain | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events- Vaccination 1 | Systemic Event- Fever | 1 Participants |
Primary
Part A: Number of Participants With Solicited Adverse Events: Vaccination 2
Solicited adverse reactions (ARs) (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema, and injection site induration/swelling. Systemic ARs included: body temperature (oral), generalized myalgia (muscle ache or pain), generalized arthralgia (joint ache or pain), headache, fatigue/malaise (unusual tiredness), nausea/vomiting, chills, and rash. Data for this outcome measure is reported up to 7 days after the second study vaccination only. A summary of all serious AEs (SAEs) and all nonserious AEs (Other), regardless of causality, is in Reported Adverse Events section.
Time frame: Up to 7 days post-vaccination 2 (Day 29 to Day 36)
Population: The Safety set included all participants in Randomized Set who received at least 1 dose of study drug (mRNA-1325 or placebo) and provided post vaccination 2 safety data.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Fever | 1 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Fatigue | 11 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Vomiting | 4 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Pain | 19 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Diarrhea | 2 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Tenderness | 22 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Generalized Arthralgia | 6 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Generalized Myalgia | 13 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Swelling | 0 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Headache | 9 Participants |
| mRNA-1325 10 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Redness | 1 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Swelling | 0 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Fever | 2 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Generalized Arthralgia | 7 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Tenderness | 19 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Headache | 11 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Vomiting | 4 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Fatigue | 12 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Redness | 0 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Pain | 19 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Diarrhea | 0 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Generalized Myalgia | 10 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Generalized Myalgia | 12 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Headache | 10 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Pain | 19 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Tenderness | 20 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Swelling | 1 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Redness | 2 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Fever | 7 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Vomiting | 7 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Diarrhea | 1 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Fatigue | 11 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Generalized Arthralgia | 6 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Redness | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Generalized Arthralgia | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Fatigue | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Tenderness | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Pain | 1 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Local Event- Swelling | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Generalized Myalgia | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Diarrhea | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Vomiting | 0 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Headache | 2 Participants |
| Placebo | Part A: Number of Participants With Solicited Adverse Events: Vaccination 2 | Systemic Event- Fever | 0 Participants |
Primary
Part A: Number of Participants With Unsolicited Adverse Events
An unsolicited AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The treatment-emergent AEs are defined as any event not present before exposure to study drug or any event already present that worsened in intensity or frequency after exposure. A summary of all SAEs and all nonserious AEs (Other) reported up to the end of the study, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Up to Day 392 (all AEs considered an SAE were collected till end of study [Day 392]; the Other AEs [non-SAE] were collected up to Day 57)
Population: The Safety set included all participants in Randomized Set who received at least 1 dose of study drug (mRNA-1325 or placebo).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| mRNA-1325 10 mcg | Part A: Number of Participants With Unsolicited Adverse Events | 14 Participants |
| mRNA-1325 25 mcg | Part A: Number of Participants With Unsolicited Adverse Events | 9 Participants |
| mRNA-1325 100 mcg | Part A: Number of Participants With Unsolicited Adverse Events | 14 Participants |
| Placebo | Part A: Number of Participants With Unsolicited Adverse Events | 6 Participants |
Primary
Part B: Number of Participants With Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)
An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions was a congenital anomaly/birth defect, or was an important medical event. AESIs included potentially immune-mediated medical conditions (autoimmune or autoinflammatory diseases) that may have the theoretical potential for association with novel vaccines. A summary of all SAEs and all nonserious AEs (Other), regardless of causality, is located in the Reported Adverse Events section.
Time frame: Up to 1 year post-vaccination (Day 392)
Population: The Safety set included all participants in Randomized Set who received at least 1 dose of study drug (mRNA-1325 or placebo).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| mRNA-1325 10 mcg | Part B: Number of Participants With Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) | SAE | 1 Participants |
| mRNA-1325 10 mcg | Part B: Number of Participants With Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) | AESI | 0 Participants |
| mRNA-1325 25 mcg | Part B: Number of Participants With Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) | AESI | 0 Participants |
| mRNA-1325 25 mcg | Part B: Number of Participants With Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) | SAE | 0 Participants |
| mRNA-1325 100 mcg | Part B: Number of Participants With Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) | SAE | 0 Participants |
| mRNA-1325 100 mcg | Part B: Number of Participants With Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) | AESI | 0 Participants |
| Placebo | Part B: Number of Participants With Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) | SAE | 0 Participants |
| Placebo | Part B: Number of Participants With Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) | AESI | 0 Participants |
Secondary
Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus
GMT 95% CI is calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.
Time frame: Baseline, 28 days post each vaccination (Days 29 and 57)
Population: The per-protocol set included all participants in the randomized set who did not have a major protocol violation, received the full dose of the assigned investigational product within the acceptable vaccination window, had blood collection within accepted visit windows, and had a pre-vaccination and at least 1 serum sample from the post-vaccination immunogenicity testing period available for testing. Here, number analyzed signifies those participants who were evaluable at specified time points.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| mRNA-1325 10 mcg | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Baseline | 5.4 Titer |
| mRNA-1325 10 mcg | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Day 57 | 10.3 Titer |
| mRNA-1325 10 mcg | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Day 29 | 5.8 Titer |
| mRNA-1325 25 mcg | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Baseline | 5.0 Titer |
| mRNA-1325 25 mcg | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Day 57 | 6.6 Titer |
| mRNA-1325 25 mcg | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Day 29 | 5.6 Titer |
| mRNA-1325 100 mcg | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Day 29 | 5.2 Titer |
| mRNA-1325 100 mcg | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Baseline | 5.0 Titer |
| mRNA-1325 100 mcg | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Day 57 | 7.7 Titer |
| Placebo | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Baseline | 5.0 Titer |
| Placebo | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Day 57 | 5.0 Titer |
| Placebo | Part A: Geometric Mean Titer of Neutralizing Serum Antibody (PRNT50) to Zika Virus | Day 29 | 5.0 Titer |